The Efficacy and Safety of Ta1 for Sepsis

Inclusion Criteria: 1. Age ≥ 18 and ≤85; 2. Signed informed consent signed; 3. Diagnosed as a sepsis according to the sepsis diagnosis criteria in "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016": at least one acute severe organ dysfunction related to sepsis, and total SOFA scores ≥2; 4. Infected focus are confirmed or suspected and satisfy at least one of the followings: 1. pathogenic microbes grow in blood or at aseptic locations 2. presence of abscess or partially-infected tissues 3. suspected infection identified by at least one of the following evidences: * leukocytes at normal aseptic locations * organic perforation (confirmed by imaging evidence, examination result or intestinal content leak during drainage) * Imaging evidence of pneumonia accompanied by purulent secretion * Related syndromes with high infection risk (cholangitis for example) Exclusion Criteria: 1. History of organ or bone marrow transplantation; 2. Acute phase connective tissue diseases (such as rheumatoid diseases, systemic lupus erythematosus) and glomerulonephritis; 3. Under pregnancy or in suckling period; 4. Presence of hematologic malignancies; 5. The patient has received radiotherapy or chemotherapy within the past 30 days; 6. The patient is inclined to stop or cancel the artificial intervention for sustaining life, in other words, has abandoned treatment; 7. The patient has in the past 30 days received immunosuppressive drugs (tripterygium wilfordii, CellCept, cyclophosphamide, FK506, etc.) or received continuous treatment with prednisolone \>10 mg/day (or the same dose of other hormones); 8. The patient could die of an underlying disease within 28 days or is in end-stage; 9. The patient has undergone CPR in the 72 hours before signing the informed consent and the neuromechanism has not fully recovered (GCS score ≤ 8); 10. The patient has in the past 30 days used thymosin or undergone certain clinical drug or instrument trials which could affect immunity (such as Xuebijing, ulinastatin and CRRT); 11. The patient has a medical history of allergy or intolerance to thymalfasin; 12. The source of infection cannot be contained, for example: infections that cannot be handled during surgical operations and drainage.